Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients
- PMID: 20110249
- DOI: 10.1093/ndt/gfp762
Study design and subject baseline characteristics in the ADVANCE Study: effects of cinacalcet on vascular calcification in haemodialysis patients
Abstract
Background: The ADVANCE (A Randomized Study to Evaluate the Effects of Cinacalcet plus Low-Dose Vitamin D on Vascular Calcification in Subjects with Chronic Kidney Disease Receiving Haemodialysis) Study objective is to assess the effect of cinacalcet plus low-dose active vitamin D versus flexible dosing of active vitamin D on progression of coronary artery calcification (CAC) in haemodialysis patients. We report the ADVANCE Study design and baseline subject characteristics.
Methods: ADVANCE is a multinational, multicentre, randomized, open-label study. Adult haemodialysis patients with moderate to severe secondary hyperparathyroidism (intact parathyroid hormone [iPTH] >300 pg/mL or bio-intact PTH >160 pg/mL) and baseline CAC score >or=30 were stratified by CAC score (>or=30-399, >or=400-999, >or=1000) and randomized in a 1:1 ratio to cinacalcet (30-180 mg/day) plus low-dose active vitamin D (cinacalcet group) or flexible dosing of active vitamin D alone (control). The study had three phases: screening, 20-week dose titration and 32-week follow-up. CAC scores obtained by cardiac computed tomography were determined at screening and weeks 28 and 52. The primary end point was percentage change in CAC score from baseline to Week 52.
Results: Subjects (n = 360) were randomized to cinacalcet or control. Mean age was 61.5 years, 43% were women, and median dialysis vintage was 36.7 months (range, 2.7-351.5 months). The baseline geometric mean CAC score by the Agatston method was 548.7 (95% confidence interval, 480.5-626.6). Baseline CAC score was independently associated with age, sex, dialysis vintage, diabetes and iPTH. Subjects also had extensive aortic and valvular calcification at baseline.
Conclusions: Subjects enrolled in ADVANCE have extensive CAC at baseline. The ADVANCE Study should help determine whether cinacalcet attenuates progression of vascular calcification.
Comment in
-
Effects of cinacalcet on vascular calcification in haemodialysis patients.Nephrol Dial Transplant. 2010 Aug;25(8):2800. doi: 10.1093/ndt/gfq307. Epub 2010 May 25. Nephrol Dial Transplant. 2010. PMID: 20501465 Clinical Trial. No abstract available.
Similar articles
-
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.Nephrol Dial Transplant. 2011 Apr;26(4):1327-39. doi: 10.1093/ndt/gfq725. Epub 2010 Dec 8. Nephrol Dial Transplant. 2011. PMID: 21148030 Clinical Trial.
-
Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study.Nephrol Dial Transplant. 2013 Jan;28(1):146-52. doi: 10.1093/ndt/gfs356. Epub 2012 Sep 30. Nephrol Dial Transplant. 2013. PMID: 23028103 Clinical Trial.
-
Presence of valvular calcification predicts the response to cinacalcet: data from the ADVANCE study.J Heart Valve Dis. 2013 May;22(3):391-9. J Heart Valve Dis. 2013. PMID: 24151766 Clinical Trial.
-
Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.J Ren Nutr. 2006 Jul;16(3):253-8. doi: 10.1053/j.jrn.2006.04.010. J Ren Nutr. 2006. PMID: 16825031 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Polymorphism in the human matrix Gla protein gene is associated with the progression of vascular calcification in maintenance hemodialysis patients.Clin Exp Nephrol. 2013 Dec;17(6):882-9. doi: 10.1007/s10157-013-0785-9. Epub 2013 Mar 16. Clin Exp Nephrol. 2013. PMID: 23504408
-
Gender-Related Differences in Chronic Kidney Disease-Associated Vascular Calcification Risk and Potential Risk Mediators: A Scoping Review.Healthcare (Basel). 2021 Aug 1;9(8):979. doi: 10.3390/healthcare9080979. Healthcare (Basel). 2021. PMID: 34442116 Free PMC article.
-
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.Cochrane Database Syst Rev. 2014;2014(12):CD006254. doi: 10.1002/14651858.CD006254.pub2. Epub 2014 Dec 9. Cochrane Database Syst Rev. 2014. PMID: 25490118 Free PMC article.
-
Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.J Diabetes Complications. 2019 Nov;33(11):107423. doi: 10.1016/j.jdiacomp.2019.107423. Epub 2019 Sep 3. J Diabetes Complications. 2019. PMID: 31537413 Free PMC article.
-
A prospective randomized pilot study on intermittent post-dialysis dosing of cinacalcet.Int Urol Nephrol. 2014 Jan;46(1):113-9. doi: 10.1007/s11255-013-0418-y. Epub 2013 Mar 26. Int Urol Nephrol. 2014. PMID: 23529273 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical